For example, DNA copy number amplifications in KRAS, ERBB2, MET and FGFR1 have been found to be predictors of poor prognosis and resistance to anti-EGFR therapy for CRC patients [13, 14]. This evidence concerns the gene ERBB2 and colorectal carcinoma.